Cyteir Therapeutics
Cancer

Cancer

Genomic Instability is a Cancer Driver

Cyteir Scientific Approach - Cancer
In cancer, there are two types of causative genes: Oncogenes are genes that become activated in a cancer and cause its growth; tumor suppressor genes are genes that normally prevent cancer development but are turned off in cancer cells. Both the gain of function in oncogenes and the loss of function in tumor suppressors can lead to DNA damage and genomic instability. Ongoing DNA damage causes tumor evolution, cancer progression, and therapy resistance. However, excessive DNA damage in cancer cells is also an “Achilles heel” and targeting specific DNA repair mechanisms can induce synthetic lethality in cancer cells.

To date, synthetic lethal therapies have focused on loss-of-function mutations (i.e. tumor suppressors). In contrast, Cyteir is developing a new generation of synthetic lethal therapies that target gain-of-function genetic abnormalities (i.e. oncogenes).

Through the modulation of RAD51 we’ve demonstrated an ability to selectively target and eliminate AID+ diseased cells with high tolerability and minimal off target effects in healthy cells.

Cyteir Scientific Approach - Cancer